Sign In
Buy ALLO
$2.00
-0.0500 (-2.44%)
At Close: Jun 03, 2026
Allogene: Continuing To Deliver Solid Data In Allogeneic CART
01:15pm, Saturday, 19'th Jun 2021
Allogene is a leading allogeneic CART developer. It is slowly delivering strong data for its programs.
Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Conferences
08:30am, Thursday, 20'th May 2021
SOUTH SAN FRANCISCO, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR
SOUTH SAN FRANCISCO, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR
Allogene Therapeutics to Host Virtual CD19 Forum on May 19, 2021
08:30am, Wednesday, 12'th May 2021
SOUTH SAN FRANCISCO, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR
Allogene (ALLO) Q1 Earnings & Sales Beat, Pipeline Advances
11:16am, Thursday, 06'th May 2021
Allogene (ALLO) beats earnings and revenue estimates in the first quarter. Stock gains 1.7%.
Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q1 2021 Results - Earnings Call Transcript
10:33pm, Wednesday, 05'th May 2021
Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q1 2021 Results - Earnings Call Transcript
Allogene Therapeutics (ALLO) Reports Q1 Loss, Tops Revenue Estimates
07:10pm, Wednesday, 05'th May 2021
Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 47.92% and 56.54%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
SOUTH SAN FRANCISCO, Calif. and PARIS, April 28, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CA
Allogene Therapeutics to Report First Quarter Financial Results on May 5, 2021
08:30am, Tuesday, 27'th Apr 2021
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET
Allogene (ALLO) CAR T Therapy for Myeloma Gets FDA RMAT Tag
11:16am, Thursday, 22'nd Apr 2021
FDA grants RMAT designation to Allogene's (ALLO) CAR T cell product candidate for multiple myeloma, ALLO-715. The designation will help accelerate development and review of the candidate.
SOUTH SAN FRANCISCO, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC
Immunocore: 'Off-The-Shelf' T Cell Therapy
11:13am, Monday, 12'th Apr 2021
Immunocore: 'Off-The-Shelf' T Cell Therapy
SOUTH SAN FRANCISCO, Calif. and STAMFORD, Conn., April 12, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of all
SOUTH SAN FRANCISCO, Calif., April 10, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC
Allogene: World Leader In Allogeneic CAR-T
06:32am, Monday, 05'th Apr 2021
Allogene is a world leader in allogeneic CAR-T.
